Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Recruiting · NCT02253251 · Observational (researchers observe without assigning treatment) · Lead sponsor: MiraKind
View the official record on ClinicalTrials.gov →Interventions studied
KRAS-variant and microRNA binding site mutation testing
What this trial is about
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Exclusion criteria
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
Where it is running
1 location listed across 1 US state.
- MiraKind - Los Angeles, California, United States